Antidepressant-Induced Emotional Blunting: Diagnosis, Mechanisms and Management

In a nutshell

Antidepressant-induced emotional blunting (AIEB) is a reduction in the ability to experience emotions (both positive and negative) that affects ~40–60% of patients on antidepressants, particularly SSRIs and SNRIs. Patients describe feeling emotionally “numb” or detached, with dampened reactions to typically emotional situations. Management centers on dose reduction (first-line) or switching to agents with lower risk, like bupropion.

• When to screen for antidepressant-induced emotional blunting:
  • All patients on SSRIs/SNRIs (routine screening recommended)
  • Patients reporting sexual dysfunction (frequent co-occurrence)
  • Reports of personality change or relationship strain
  • Higher doses or recent dose increases
• Evidence-based management strategies:
  • First-line: Reduce antidepressant dose by 25-50% if clinically feasible
  • Switching options:
    • Bupropion (lowest risk at 33%, addresses both emotional blunting and sexual dysfunction)
    • Vortioxetine (improvement in open-label studies, though manufacturer-sponsored data limits conclusions)
    • Mirtazapine or agomelatine (mechanistic rationale via 5-HT2C blockade, limited clinical evidence)
  • Augmentation: Add bupropion 150 mg/day SR/XL to facilitate SSRI dose reduction
  • Avoid: Switching within the SSRI class (ineffective), routine use of antipsychotics (unfavorable risk-benefit)

Definition

Core Clinical Features

• Antidepressant-Induced Emotional Blunting (AIEB) is a patient-reported reduction in the capacity to experience the full spectrum of human emotions that begins or worsens after antidepressant initiation or dose increase ^[1,2]
  • Positive emotions affected:
    • Joy, love, excitement
    • Enthusiasm, passion, affection
  • Negative emotions affected:
    • Sadness, fear, anger
    • Worry, grief, frustration
• Patients often struggle to articulate this state, using evocative descriptors like feeling emotionally “dulled,” “numbed,” “flattened,” or “blocked” ^[3]
• Shift from affective to cognitive processing
  • Where emotional reactions would normally occur, patients describe having thoughts about events rather than genuine feelings ^[1]
  • This leads to a state of emotional detachment from experiences and relationships
  • Patients may report feeling like “observers” of their own lives rather than participants
• Many patients report fundamental changes in their personality ^[4]
  • Loss of their characteristic emotional responses
  • Disconnect from their pre-treatment emotional identity
• Clinical significance
  • Current estimates indicate that ~40-60% of antidepressant users experience AIEB, making it a significant clinical concern that can contribute to nonadherence and discontinuation ^[3,5–7]

Diagnosis

• Under-recognition: AIEB is more frequently reported by patients than recognized by prescribers.
  • Up to one-third of patients never disclose these symptoms, possibly fearing they’ll be dismissed or misread as a sign of worsening depression ^[5]
• Accurate recognition requires proactive screening and differentiation from overlapping phenomena; AIEB has distinct clinical features.

Condition	Key Features	Emotional Experience	Timing / Context	Clinical Clue
Emotional Blunting	Dampened intensity of all emotions (positive & negative)	“I know I should feel happy/sad, but I don’t”	Often emerges after antidepressant start	Patient describes feeling “artificial” or “numb”
Anhedonia	Inability to experience pleasure	“Nothing brings me joy anymore”	Core symptom during depression	Negative emotions (sadness/anxiety) may still be present
Apathy	Loss of motivation, interest, or initiative	“I don’t care about anything”	Loss of drive to engage in activities	Behavioral change more prominent than affective
Residual Depression	Incomplete remission of depression	“I’m better but still feel down”	Continuous from original episode	Depressive symptoms persist

Emotional blunting vs. anhedonia

• Anhedonia is more narrowly defined as the loss of pleasure or interest in activities that were previously enjoyable, typically as part of depression.
• Emotional blunting is broader—it involves reduced intensity of both positive and negative emotions.
• A patient with emotional blunting might say they don’t strongly feel happy or sad, whereas an anhedonic patient primarily cannot feel joy but may still experience sadness or frustration ^[4]

Emotional blunting vs. apathy

• Even though some studies use apathy and blunting interchangeably, blunting refers to diminished emotional expression or feeling, whereas apathy is a lack of motivation, interest, or concern (“not caring”) ^[8,9]
• In blunting, patients may have normal drive to do things but report that emotions feel dulled.
• In true apathy, initiative and interest in activities are markedly reduced.

Residual depression vs. medication effect

• In residual depression, the patient’s muted affect comes from ongoing depressive illness (they still feel down, hopeless, or anxious).
• Patients often describe antidepressant-induced blunting as a qualitatively different state that emerges or worsens after the initiation of treatment
  • Frequently persists even as other core depressive symptoms like low mood and guilt begin to resolve ^[4]
• One clue is timing – if emotional numbing started after the medication brought mood symptoms under control, blunting is likely.
• Antidepressant-induced emotional blunting can be present even in patients whose depression is in remission.

Recognizing AIEB

• Screen for emotional blunting routinely in all patients on serotonergic antidepressants.
• Proactive assessment is essential -do not wait for patients to complain of “numbness”.
• Many patients will not volunteer the symptom spontaneously.
• Be especially vigilant with higher doses and co-occurring sexual dysfunction ^[10,11]

Structured Assessment

1. Open-ended screen “Is there any change from what is usual for you in how you’ve been experiencing emotions?”
2. Targeted questions^[12]
   • Differentiate depression: “How does this numbness compare with your worst depression?”
   • Global affect: “Any changes in positive emotions (joy/excitement) or normal reactions (anger/irritation)?”
   • Empathy/relationships: “Have you or others noticed changes in how you respond to others’ feelings?”
   • Temporal link: “Did this start or worsen after starting/increasing the antidepressant? Did it remit off medication or with dose reduction?”
3. Collateral sources
   • With consent, ask close contacts about facial expression, vocal tone, and emotional reactions.

Screening Tools

• Oxford Depression Questionnaire (ODQ) – validated, patient-rated scale designed to measure emotional blunting ^[3]
  • Quantifies severity and tracks changes over time ^[13]
  • Facilitates targeted discussion of the emotional domains most affected

Mechanisms

Serotonin Frontal Lobe Modulation

• SSRIs/SNRIs increase synaptic serotonin availability, altering fronto-limbic circuits ^[6]
  • Key regions affected include: Prefrontal cortex (PFC), amygdala, and their interconnections
  • In depression, these circuits demonstrate hyper-reactivity to negative stimuli while showing blunted responses to positive stimuli
  • Treatment paradox: While SSRIs effectively “cool down” this hyper-reactivity, they can cause generalized emotional dampening as an unintended consequence ^[14]
• Chronic SSRI treatment produces bidirectional effects on emotional processing circuits
  • Increased PFC–amygdala coupling; decreased amygdala reactivity to negative cues ^[15]
  • Net effect: While therapeutically beneficial for anxiety and depression, these changes can inadvertently reduce emotional responsiveness across domains ^[6]

Dopamine Suppression Hypothesis

• The brain’s serotonin and dopamine systems are intricately linked and often have an inverse relationship.
• 5-HT2C activation can down-regulate dopamine in mesolimbic (reward processing) and mesocortical (motivation and executive function) pathways ^[16]
• Dopaminergic suppression leads to:
  • Reduced reward sensitivity
  • Reduced motivation and drive
  • Flattened emotional salience
• Non-serotonergic antidepressants like bupropion show significantly lower rates of emotional blunting, supporting this hypothesis ^[5]

The Reinforcement Learning Deficit Model

• A 2023 study revealed that SSRIs specifically impair probabilistic reversal learning ^[10]
  • Definition: The ability to adapt behavior when reward/punishment contingencies change
  • This process underlies how we learn from emotional experiences and adjust our responses
  • Participants could process consequences intellectually, but couldn’t feel their emotional impact
• Reduced reinforcement sensitivity correlated with:
  • Emotional blunting: Diminished pleasure from social and environmental rewards
  • Sexual dysfunction: Reduced response to sexual stimuli (orgasm difficulty)
• Clinical implication:
  • When identifying either emotional blunting or sexual dysfunction, routinely screen for the other

Comparison: Higher- vs. Lower-Risk Antidepressants

• The balance of evidence suggests potent serotonergic agents (SSRIs/SNRIs) carry the highest signal for antidepressant-induced emotional blunting (AIEB), while non-serotonergic and some multimodal agents show a lower signal of risk.
  • These estimates come primarily from side-effect surveys and observational studies, with heterogeneous measures and substantial self-report; this limits precise cross-drug comparisons ^[8]
  • Evidence gaps: for several agents (TCAs, MAOIs, vilazodone, vortioxetine, mirtazapine) comparative, long-term data are limited, precluding firm conclusions.

Table 1: Comparative Risk of Emotional Blunting Across Antidepressant Classes

Antidepressant Class	Risk Level	Clinical Notes	Evidence Base (type/quality)
SSRIs (fluoxetine, sertraline, escitalopram, paroxetine)	High	Reported 20–92%; most series 40–60% [8,17] Some analyses note a ≤6% increase post-acute treatment and 20–25% persistence in subsets [18]	Case reports/series + surveys/observational [5,19–22]
SNRIs (venlafaxine, duloxetine)	High	Overall 5.8–50% [8]; some surveys report higher rates with duloxetine [5]	Case reports + internet/observational surveys [5,23,24]
TCAs (amitriptyline, clomipramine)	Moderate	Limited data (≈30–50%); possibly higher with serotonergic TCAs (e.g., clomipramine) [5]	Sparse/indirect comparative data Representation in mixed surveys; limited class-specific, head-to-head AIEB outcomes [8,20]
Multimodal (vilazodone, vortioxetine)	Low	Vortioxetine: improvement after switch from SSRI/SNRI in open-label cohorts [25,26] Vilazodone: theoretical lower risk (5-HT1A partial agonism); limited comparative data [27,28]	Internet survey reported lower “emotional numbing” with vilazodone/vortioxetine vs. escitalopram/duloxetine [23]; open-label switch data for vortioxetine [25,26]; randomized augmentation trial secondary analysis [13]
Bupropion (NDRI)	Low	Lower AIEB signal vs SRIs (surveys/observational; some reports ≈33%) [5,8,17]	Surveys/observational; limited controlled data [8]
Agomelatine (MT1/MT2 agonist; 5-HT2C antagonist)	Low	Comparative reports suggest less blunting vs SSRIs [6,8]	One double-blind RCT: Agomelatine vs escitalopram RCT with fewer “lack of emotional intensity” complaints on agomelatine [29]; affective-processing study in volunteers [30]
Mirtazapine (NaSSA; α₂-antagonist; 5-HT2/5-HT3 blockade)	Low?	Non-SRI mechanism; theoretical lower risk; early human emotional-processing effects consistent with preserved positive affect [31]	Mechanistic + indirect clinical signals [31]; inclusion in mixed surveys/series without clear excess AIEB signal [8]
MAOIs (phenelzine, tranylcypromine)	Unclear	No robust quantified data; mechanism (↑DA/NE) suggests potentially lower risk	Mechanistic/clinical experience; quantified class-specific AIEB data lacking [8]

• Key Clinical Takeaways
  • Highest signal: SSRIs/SNRIs. When emotional preservation is a priority, consider non-serotonergic or multimodal options.
  • Lower-signal options: Bupropion and agomelatine are reasonable considerations; vortioxetine may improve AIEB after SSRI/SNRI switch based on open-label evidence ^[25,26] and a randomized secondary analysis ^[13]
  • Caveats: Cross-study rate comparisons are constrained by measurement heterogeneity and self-report; several classes still lack adequate head-to-head, long-term data.

Management Strategies

• The goal is to restore the patient’s emotional vitality while maintaining mood/anxiety control.
• A systematic, stepwise approach optimizes outcomes and minimizes treatment disruption.

First-Line Strategies

Dose reduction

• Rationale: AIEB appears dose-dependent and is often reversible ^[6,32]
• In ambiguous cases where it’s unclear if symptoms represent residual depression or a medication side effect, one protocol suggests a brief dose increase can be considered – if blunting worsens, this confirms drug-induced etiology and supports subsequent dose reduction ^[8]
• Implementation:
  • Reduce the current antidepressant dose by 25–50%, reassessing every 2–4 weeks for changes in blunting and mood
  • Consider that patients on already low doses (e.g., sertraline 50 mg/day) may require switching rather than further dose reduction to avoid subtherapeutic levels
• Monitoring: Close mood surveillance – if relapse signs appear, dose may need readjustment to prevent MDD recurrence
• While recommended in systematic reviews and expert opinion as a first-line strategy, dose reduction lacks robust RCT validation for emotional blunting specifically ^[8]

Watchful waiting

• Rationale: Some SSRI side effects diminish over time; AIEB may show spontaneous improvement in early treatment phases ^[33,34]
• Appropriate when: Early treatment (first 4–6 weeks), mild symptoms, no functional impairment, patient preference for conservative management.
• Duration: 2–4 weeks with close monitoring.
• Monitor to ensure blunting doesn’t persist unaddressed or cause functional impairment.

Switching Strategies

• Aim: Switching is intended to find an antidepressant with a mechanism less likely to dull emotions.
• The evidence for any particular switch is limited (mostly case reports or open-label studies) ^[6,8], so the choice must be individualized.
• When switching, cross-tapering or washout strategies should be employed as appropriate to minimize withdrawal or destabilization of mood.

Bupropion

• Low rates of AIEB (33%) among antidepressants in survey data ^[5]
• “Very few reports” in qualitative studies of emotional blunting compared to serotonergic agents ^[17]
• Bupropion’s mechanism (NE/DA reuptake inhibition; no direct serotonergic effect) may preserve or enhance motivation and emotional engagement.
• Clinical advantages:
  • Addresses both emotional blunting and sexual dysfunction
  • Maintains robust antidepressant efficacy
  • May enhance energy and motivation
• Considerations: Contraindicated in seizure and eating disorders; may exacerbate anxiety/insomnia—monitor and titrate.

Vortioxetine

• Open-label studies report that vortioxetine may improve antidepressant-induced emotional blunting:
  • Significant improvement of emotional blunting after switching reported in an open-label trial (n=143) ^[25]
  • Approximately 70% of patients no longer experienced emotional blunting after 8 weeks on vortioxetine ^[26]
  • In the PREDDICT trial, vortioxetine was associated with reductions in ODQ total and subscales at 8 weeks, maintained at 3- and 6-month follow-up; celecoxib augmentation conferred no added benefit ^[13]
  • Limitations: Studies come from non-placebo-controlled research – some sponsored by the manufacturer – creating risk of bias. PREDDICT findings derive from a secondary analysis and were not designed to test AIEB as a primary endpoint.
  • Higher-quality independent randomized controlled trials are needed.
• Dosing: 10-20 mg daily, with many patients requiring 20 mg for optimal response ^[26]
• Cost and access can be factors, as vortioxetine may be more expensive

Other antidepressants (mechanistic considerations)

• Mechanistic hypothesis: Some researchers propose that agents with different mechanisms of action – such as reboxetine, mirtazapine, or agomelatine – may selectively modify biological factors underlying the processing of happiness and sadness while preserving other emotional responses ^[30,31]
  • However, this hypothesis requires further investigation and robust clinical validation before definitive conclusions can be drawn.
• Consider a mechanistic switch to an antidepressant that enhances norepinephrine/dopamine rather than serotonin reuptake ^[8]
• Although evidence is limited, mirtazapine (which blocks 5-HT2C receptors and increases norepinephrine) or agomelatine (which boosts dopamine via 5-HT2C blockade) may be alternatives ^[29,35]
  • For mirtazapine, note that direct clinical evidence specific to reversing SSRI-related blunting is lacking; theoretical rationale is based on its pharmacology—α₂‑antagonism combined with 5‑HT₂A/₂C blockade

Switching within the SSRI/SNRI class

• Generally low-yield and not recommended when the target symptom is AIEB ^[36]
• While it is sometimes effective for other side effects due to idiosyncratic patient responses, it is unlikely to resolve emotional blunting as the underlying serotonergic mechanism remains unchanged ^[8]
• In SSRI-treated patients with AIEB, switching to duloxetine (SNRI) did not outperform switching to escitalopram (SSRI) ^[36]
• Reserve for cases where other factors drive the switch (e.g., drug interactions, prior response, tolerability, formulary requirements)

Augmentation Strategies

• Bupropion
  • Low-dose bupropion (e.g., 150 mg/day sustained-release) added to an SSRI/SNRI is a common strategy to address blunting and sexual dysfunction ^[8]
  • While evidence for general depression augmentation is mixed ^[37], here the aim is side-effect mitigation (dopaminergic “antidote”)
  • Counteracts serotonin-induced dopamine suppression in reward pathways
  • Benefits:
    • Can facilitate SSRI/SNRI dose reduction
    • Addresses both emotional blunting and sexual dysfunction
    • Well-established safety profile in combination
• Stimulant or dopamine agonist:
  • Low-dose methylphenidate or bromocriptine (e.g., 2.5 mg/day) has been reported in select cases ^[38]
  • This approach directly targets the dopamine suppression hypothesis, but should be used with caution and monitoring for insomnia or agitation
• Low-dose antipsychotics
  • Generally not recommended due to unfavorable risk-benefit ratio for a quality-of-life side effect
  • Limited evidence:
    • An open-label study showed olanzapine (~5 mg/day) improved SSRI-induced apathy in all measures ^[39]
    • Case report and small series show marked apathy relief after ~6 weeks of adjunct aripiprazole ^[40]
  • Mechanism: 5-HT2A/2C antagonism with dopamine modulation may rebalance neurotransmitter effects
  • Risk-benefit concerns: Substantial risks (weight gain, metabolic syndrome, sedation) often outweigh benefits for quality-of-life side effect

Non-pharmacologic

• Psychoeducation + family briefing:
  • Clarify that AIEB is medication-associated, not indifference; misattribution can strain relationships and adherence ^[4]
• Behavioral activation:
  • Maintain engagement in meaningful activities despite reduced enjoyment; schedule previously enjoyed activities even if the “spark” is reduced ^[41]

Monitoring and Follow-Up

• Instrument: ODQ for AIEB tracking ^[42].
• Timeline:
  • Reassess 2–4 weeks after an intervention
  • Monthly monitoring until resolution
  • Co-screen for sexual dysfunction given 80% correlation ^[11]

References

1. Marazziti, D., Mucci, F., Tripodi, B., Carbone, M. G., Muscarella, A., Falaschi, V., & Baroni, S. (n.d.). Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs. Clinical Neuropsychiatry, 16(2), 75–85. Retrieved July 10, 2025, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650205/
2. Szmulewicz, A., Samamé, C., Caravotta, P., Martino, D. J., Igoa, A., Hidalgo-Mazzei, D., Colom, F., & Strejilevich, S. A. (2016). Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: Clinical and theoretical implications. International Journal of Bipolar Disorders, 4, 6. https://doi.org/10.1186/s40345-016-0047-3
3. Price, J., Cole, V., Doll, H., & Goodwin, G. M. (2012). The Oxford Questionnaire on the Emotional Side-effects of Antidepressants (OQuESA): Development, validity, reliability and sensitivity to change. Journal of Affective Disorders, 140(1), 66–74. https://doi.org/10.1016/j.jad.2012.01.030
4. Price, J., Cole, V., & Goodwin, G. M. (2009). Emotional side-effects of selective serotonin reuptake inhibitors: Qualitative study. The British Journal of Psychiatry: The Journal of Mental Science, 195(3), 211–217. https://doi.org/10.1192/bjp.bp.108.051110
5. Goodwin, G. M., Price, J., De Bodinat, C., & Laredo, J. (2017). Emotional blunting with antidepressant treatments: A survey among depressed patients. Journal of Affective Disorders, 221, 31–35. https://doi.org/10.1016/j.jad.2017.05.048
6. Ma, H., Cai, M., & Wang, H. (2021). Emotional Blunting in Patients With Major Depressive Disorder: A Brief Non-systematic Review of Current Research. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.792960
7. Christensen, M. C., Ren, H., & Fagiolini, A. (2022). Emotional blunting in patients with depression. Part IV: Differences between patient and physician perceptions. Annals of General Psychiatry, 21(1), 22. https://doi.org/10.1186/s12991-022-00391-5
8. Masdrakis, V. G., Markianos, M., & Baldwin, D. S. (2023). Apathy associated with antidepressant drugs: A systematic review. Acta Neuropsychiatrica, 35(4), 189–204. https://doi.org/10.1017/neu.2023.6
9. Barnhart, W. J., Makela, E. H., & Latocha, M. J. (2004). SSRI-induced apathy syndrome: A clinical review. Journal of Psychiatric Practice, 10(3), 196–199. https://doi.org/10.1097/00131746-200405000-00010
10. Langley, C., Armand, S., Luo, Q., Savulich, G., Segerberg, T., Søndergaard, A., Pedersen, E. B., Svart, N., Overgaard-Hansen, O., Johansen, A., Borgsted, C., Cardinal, R. N., Robbins, T. W., Stenbæk, D. S., Knudsen, G. M., & Sahakian, B. J. (2023). Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: A double-blind, placebo-controlled semi-randomised study. Neuropsychopharmacology, 48(4), 664–670. https://doi.org/10.1038/s41386-022-01523-x
11. Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., & Manber, R. (2002). Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? The International Journal of Neuropsychopharmacology, 5(2), 147–151. https://doi.org/10.1017/S1461145702002870
12. Emotional blunting/ flattening (numbing, dulling, indifference). (n.d.). Simple; Practical Mental Health. Retrieved August 9, 2025, from https://simpleandpractical.com/emotional-blunting-flattening-numbing-dulling-indifference-apathy/
13. Sampson, E., Kavakbasi, E., Mills, N. T., Hori, H., Schubert, K. O., Fourrier, C., & Baune, B. T. (2024). Emotional Blunting in Depression in the PREDDICT Clinical Trial: Inflammation-Stratified Augmentation of Vortioxetine With Celecoxib. International Journal of Neuropsychopharmacology, 27(3), pyad066. https://doi.org/10.1093/ijnp/pyad066
14. McCabe, C., Mishor, Z., Cowen, P. J., & Harmer, C. J. (2010). Diminished Neural Processing of Aversive and Rewarding Stimuli During Selective Serotonin Reuptake Inhibitor Treatment. Biological Psychiatry, 67(5), 439–445. https://doi.org/10.1016/j.biopsych.2009.11.001
15. Chen, C.-H., Suckling, J., Ooi, C., Fu, C. H. Y., Williams, S. C. R., Walsh, N. D., Mitterschiffthaler, M. T., Pich, E. M., & Bullmore, E. (2008). Functional Coupling of the Amygdala in Depressed Patients Treated with Antidepressant Medication. Neuropsychopharmacology, 33(8), 1909–1918. https://doi.org/10.1038/sj.npp.1301593
16. Demireva, E. Y., Suri, D., Morelli, E., Mahadevia, D., Chuhma, N., Teixeira, C. M., Ziolkowski, A., Hersh, M., Fifer, J., Bagchi, S., Chemiakine, A., Moore, H., Gingrich, J. A., Balsam, P., Rayport, S., & Ansorge, M. S. (2020). 5-HT2C receptor blockade reverses SSRI-associated basal ganglia dysfunction and potentiates therapeutic efficacy. Molecular Psychiatry, 25(12), 3304–3321. https://doi.org/10.1038/s41380-018-0227-x
17. Camino, S., Strejilevich, S. A., Godoy, A., Smith, J., & Szmulewicz, A. (2023). Are all antidepressants the same? The consumer has a point. Psychological Medicine, 53(9), 4004–4011. https://doi.org/10.1017/S0033291722000678
18. Peters, E. M., Balbuena, L., & Lodhi, R. J. (2022). Emotional blunting with bupropion and serotonin reuptake inhibitors in three randomized controlled trials for acute major depressive disorder. Journal of Affective Disorders, 318, 29–32. https://doi.org/10.1016/j.jad.2022.08.066
19. Wongpakaran, N., van Reekum, R., Wongpakaran, T., & Clarke, D. (2007). Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: A case-control study. Annals of General Psychiatry, 6, 7. https://doi.org/10.1186/1744-859X-6-7
20. van Geffen, E. C. G., van der Wal, S. W., van Hulten, R., de Groot, M. C. H., Egberts, A. C. G., & Heerdink, E. R. (2007). Evaluation of patients’ experiences with antidepressants reported by means of a medicine reporting system. European Journal of Clinical Pharmacology, 63(12), 1193–1199. https://doi.org/10.1007/s00228-007-0375-4
21. Read, J., Cartwright, C., & Gibson, K. (2014). Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Research, 216(1), 67–73. https://doi.org/10.1016/j.psychres.2014.01.042
22. Read, J., & Williams, J. (2018). Adverse Effects of Antidepressants Reported by a Large International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects. Current Drug Safety, 13(3), 176–186. https://doi.org/10.2174/1574886313666180605095130
23. Hughes, S., Lacasse, J., Fuller, R. R., & Spaulding-Givens, J. (2017). Adverse effects and treatment satisfaction among online users of four antidepressants. Psychiatry Research, 255, 78–86. https://doi.org/10.1016/j.psychres.2017.05.021
24. Sato, S., Sodeyama, N., Matsuzaki, A., & Shiratori, Y. (2020). Apathy symptoms induced by low‐dose venlafaxine: Two cases. Neuropsychopharmacology Reports, 40(2), 196–197. https://doi.org/10.1002/npr2.12104
25. Fagiolini, A., Florea, I., Loft, H., & Christensen, M. C. (2021). Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. Journal of Affective Disorders, 283, 472–479. https://doi.org/10.1016/j.jad.2020.11.106
26. Christensen, M. C., Canellas, F., Loft, H., & Montejo, Á. L. (2024). Effectiveness of Vortioxetine for the Treatment of Emotional Blunting in Patients with Major Depressive Disorder Experiencing Inadequate Response to SSRI/SNRI Monotherapy in Spain: Results from the COMPLETE Study. Neuropsychiatric Disease and Treatment, 20, 1475–1489. https://doi.org/10.2147/NDT.S473056
27. Hughes, J. R., Stead, L. F., Hartmann‐Boyce, J., Cahill, K., & Lancaster, T. (2014). Antidepressants for smoking cessation. The Cochrane Database of Systematic Reviews, 2014(1), CD000031. https://doi.org/10.1002/14651858.CD000031.pub4
28. Kalenderoglou, I. E., Nygaard, A., Vogt, C. D., Turaev, A., Pape, T., Adams, N. B. P., Newman, A. H., & Loland, C. J. (2025). Structural basis of vilazodone dual binding mode to the serotonin transporter. Research Square, rs.3.rs–5671197. https://doi.org/10.21203/rs.3.rs-5671197/v1
29. Corruble, E., de Bodinat, C., Belaïdi, C., Goodwin, G. M., & on behalf of the agomelatine study group. (2013). Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: A 24-wk randomized, controlled, double-blind trial. International Journal of Neuropsychopharmacology, 16(10), 2219–2234. https://doi.org/10.1017/S1461145713000679
30. Harmer, C. J., de Bodinat, C., Dawson, G. R., Dourish, C. T., Waldenmaier, L., Adams, S., Cowen, P. J., & Goodwin, G. M. (2011). Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. Journal of Psychopharmacology (Oxford, England), 25(9), 1159–1167. https://doi.org/10.1177/0269881110376689
31. Arnone, D., Horder, J., Cowen, P. J., & Harmer, C. J. (2009). Early effects of mirtazapine on emotional processing. Psychopharmacology, 203(4), 685–691. https://doi.org/10.1007/s00213-008-1410-6
32. Kodela, S., & Venkata, P. D. (2010). Antidepressant induced apathy responsive to dose reduction. Psychopharmacology Bulletin, 43(4), 76–79. https://www.ncbi.nlm.nih.gov/pubmed/21240154
33. Pascal Sienaert, M. D. (2014). Managing the Adverse Effects of Antidepressants. 31. https://www.psychiatrictimes.com/view/managing-adverse-effects-antidepressants
34. Christensen, M. C., Ren, H., & Fagiolini, A. (2022). Emotional blunting in patients with depression. Part I: Clinical characteristics. Annals of General Psychiatry, 21, 10. https://doi.org/10.1186/s12991-022-00387-1
35. Demyttenaere, K., Corruble, E., Hale, A., Quera-Salva, M.-A., Picarel-Blanchot, F., & Kasper, S. (2013). A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: Agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectrums, 18(3), 163–170. https://doi.org/10.1017/S1092852913000060
36. Raskin, J., George, T., Granger, R. E., Hussain, N., Zhao, G. W., & Marangell, L. B. (2012). Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: Outcomes following randomized switch to either duloxetine or escitalopram. Journal of Psychiatric Research, 46(5), 667–674. https://doi.org/10.1016/j.jpsychires.2012.02.010
37. Henssler, J., Alexander, D., Schwarzer, G., Bschor, T., & Baethge, C. (2022). Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry, 79(4), 300–312. https://doi.org/10.1001/jamapsychiatry.2021.4313
38. Schatzberg, A. F. (2019). Schatzberg’s manual of clinical psychopharmacology (Ninth edition.). American Psychiatric Association Publishing.
39. Marangell, L. B., Johnson, C. R., Kertz, B., Zboyan, H. A., & Martinez, J. M. (2002). Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: An open-label, flexible-dose study. The Journal of Clinical Psychiatry, 63(5), 391–395. https://doi.org/10.4088/jcp.v63n0503
40. Monga, V., & Padala, P. R. (2015). Aripiprazole for Treatment of Apathy. Innovations in Clinical Neuroscience, 12(9–10), 33–36. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655898/
41. Jung, M., & Han, K.-M. (2024). Behavioral Activation and Brain Network Changes in Depression. Journal of Clinical Neurology, 20(4), 362–377. https://doi.org/10.3988/jcn.2024.0148
42. Christensen, M. C., Fagiolini, A., Florea, I., Loft, H., Cuomo, A., & Goodwin, G. M. (2021). Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting. Journal of Affective Disorders, 294, 924–931. https://doi.org/10.1016/j.jad.2021.07.099